WILMINGTON, N.C.,(GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a pioneer in minimally invasive approaches to lumbar spine surgery, today announced it has received CE (Conformite Europeenne) Mark approval in the European Union to market its VEO(TM) lateral access fusion system for interbody fusions. Ken Reali, President and Chief Executive Officer of TranS1, stated, "We are very pleased to receive the CE Mark for the VEO lateral system.
This approval represents a significant milestone for TranS1 and will contribute to our efforts to become a leader in minimally invasive spine surgery. We are excited to begin executing on our commercialization strategy in Europe as we enter the third quarter."
The VEO minimally invasive lateral system features an innovative, two-stage retraction method that focuses on nerve visualization and then controlled retraction. The VEO system is designed for direct visualization of the psoas muscles and adjacent nerves prior to muscle dissection.
The VEO retractor is complemented by a full range of PEEK lateral interbody implants and a variety of ergonomic instruments. Radiopaque markers are strategically located within the implants to allow proper placement.
About TranS1 Inc.
TranS1 is a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the
AxiaLIF(R) family of products for single and two level lumbar fusion, the VEO lateral access and interbody fusion system, and the Vectre(TM) and Avatar(TM) posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. TranS1 was founded in May 2000 and is headquartered in Wilmington, North Carolina. For more information, visit www.trans1.com.